INBS reports 98.2% accuracy in codeine drug screen study; 510(k) submission on track for Sept 2026

INTELLIGENT BIO SOLUTIONS INC.

Multi-site study across 3 U.S. clinical sites: 98.2% accuracy, 94.6% sensitivity, 100% specificity for opiate codeine.
Improvement from prior Nov 2024 study: ~94% accuracy and 82% sensitivity; specificity unchanged at 100%.
Results measured against validated LC-MS/MS reference method; 70 true positives, 144 true negatives, 0 false positives.
Company accelerated filing timeline; expects to submit 510(k) application in September 2026 for U.S. market entry.
CEO Harry Simeonidis: 'we now have everything we need for our 510(k) submission.'

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.